WOOJUNG BIO Resultados de beneficios anteriores
Pasado controles de criterios 3/6
WOOJUNG BIO's earnings have been declining at an average annual rate of -0.2%, while the Life Sciences industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 4.8% per year. WOOJUNG BIO's return on equity is 4.6%, and it has net margins of 2.6%.
Información clave
-0.2%
Tasa de crecimiento de los beneficios
10.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Life Sciences | 53.7% |
| Tasa de crecimiento de los ingresos | 4.8% |
| Rentabilidad financiera | 4.6% |
| Margen neto | 2.6% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Why Investors Shouldn't Be Surprised By WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 30% Share Price Plunge
Oct 14
WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Shares Bounce 43% But Its Business Still Trails The Industry
Aug 16Revenues Working Against WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Following 26% Dive
Jun 14Is WOOJUNG BIO (KOSDAQ:215380) Weighed On By Its Debt Load?
May 23Desglose de ingresos y gastos
Cómo gana y gasta dinero WOOJUNG BIO. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 44,753 | 1,181 | 7,893 | 340 |
| 31 Mar 24 | 40,667 | -2,822 | 8,055 | 330 |
| 31 Dec 23 | 38,616 | -5,054 | 7,803 | 294 |
| 30 Sep 23 | 31,366 | -4,927 | 8,025 | 299 |
| 30 Jun 23 | 36,457 | -3,037 | 7,515 | 387 |
| 31 Mar 23 | 41,790 | -4,804 | 7,183 | 490 |
| 31 Dec 22 | 46,918 | -1,880 | 6,692 | 614 |
| 30 Sep 22 | 43,584 | -6,582 | 7,067 | 711 |
| 30 Jun 22 | 43,180 | -5,134 | 7,275 | 689 |
| 31 Mar 22 | 35,409 | -3,197 | 7,560 | 633 |
| 31 Dec 21 | 31,238 | -1,926 | 7,742 | 538 |
| 30 Sep 21 | 34,042 | -3,515 | 8,332 | 247 |
| 30 Jun 21 | 29,760 | -12,432 | 7,807 | 663 |
| 31 Mar 21 | 31,702 | -11,682 | 8,763 | 542 |
| 31 Dec 20 | 37,344 | -10,879 | 9,203 | 621 |
| 30 Sep 20 | 36,141 | -8,772 | 8,229 | 982 |
| 30 Jun 20 | 37,343 | 2,578 | 8,755 | 731 |
| 31 Mar 20 | 38,980 | 770 | 7,586 | 1,018 |
| 31 Dec 19 | 32,290 | 280 | 6,615 | 1,136 |
| 30 Sep 19 | 32,016 | -651 | 8,342 | 1,214 |
| 30 Jun 19 | 30,400 | -3,648 | 8,264 | 1,272 |
| 31 Mar 19 | 26,507 | -2,451 | 8,169 | 1,314 |
| 31 Dec 18 | 23,758 | -4,617 | 8,243 | 1,390 |
| 30 Sep 18 | 24,213 | -4,025 | 6,885 | 1,435 |
| 30 Jun 18 | 25,433 | -3,782 | 6,636 | 1,445 |
| 31 Mar 18 | 28,077 | -8,947 | 6,564 | 1,506 |
| 31 Dec 17 | 28,932 | -6,921 | 6,238 | 1,436 |
| 30 Sep 17 | 41,309 | -4,629 | 8,375 | 2,431 |
| 30 Jun 17 | 35,254 | -4,909 | 7,027 | 2,060 |
| 31 Mar 17 | 23,923 | 1,504 | 4,305 | 1,469 |
| 31 Dec 16 | 21,479 | 1,125 | 4,356 | 1,345 |
| 30 Sep 16 | 11,451 | 1,817 | 1,255 | -69 |
| 30 Jun 16 | 11,451 | 1,816 | 1,255 | -69 |
| 31 Mar 16 | 18,751 | 1,707 | 3,801 | 173 |
| 31 Dec 15 | 18,695 | 1,354 | 4,160 | 104 |
| 31 Dec 14 | 14,860 | 880 | 4,046 | 482 |
| 31 Dec 13 | 15,587 | 1,348 | 2,346 | 255 |
Ingresos de calidad: A215380 has high quality earnings.
Margen de beneficios creciente: A215380 became profitable in the past.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: A215380 has become profitable over the past 5 years, growing earnings by -0.2% per year.
Acelerando crecimiento: A215380 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Beneficios vs. Industria: A215380 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (18%).
Rentabilidad financiera
Alta ROE: A215380's Return on Equity (4.6%) is considered low.